Purpose To evaluate interreader and inter-test agreement in applying size-and necrosis-based response assessment criteria after transarterial embolization (TAE) for hepatocellular carcinoma (HCC), applying two different methods of European Association for the Study of the Liver (EASL) criteria. Methods Seventy-four patients (median age, 67 years) from a prospectively accrued study population were included in this retrospective study. Four radiologists independently evaluated CT data at 2-3 (1st follow-up, FU) and 10-12 (2nd FU) weeks after TAE and assessed treatment response using size-based (WHO, RECIST) and necrosis-based (mRECIST, EASL) criteria. Enhancing tissue was bidimensionally measured (EASL meas ) and also visually estimated (EASL est ). Interreader and inter-test agreements were assessed using intraclass correlation coefficient (ICC) and κ statistics. Results Interreader agreement for all response assessment methods ranged from moderate to substantial (κ=0.578-0.700) at 1st FU and was substantial (κ=0.716-0.780) at 2nd FU. Inter-test agreement was substantial between 1st FU; 2nd FU) and excellent between EASL meas and EASL est (κ=0.899-0.918, 1st FU; κ=0.843-0.877, 2nd FU). Conclusion Size-and necrosis-based criteria both show moderate to excellent interreader agreement in evaluating treatment response after TAE for HCC. Inter-test agreement regarding EASL meas and EASL est was excellent, suggesting that either may be used. Key points • Applying EASL criteria, visual estimation and bidimensional measurements show comparable interreader agreement.
Introduction
In selected patients with unresectable hepatocellular carcinoma (HCC), the use of transarterial chemoembolization rather than conservative treatment has been shown to improve survival [1, 2] . Other methods of transarterial therapy, including transarterial embolization, embolization with drug-eluting beads and radioembolization with yttrium-90, have also been used to treat HCC [3] [4] [5] [6] . Cross-sectional imaging techniques such as computed tomography (CT) or magnetic resonance imaging (MRI) have been recommended for assessing the response to such transarterial treatments [7] .
The response assessment criteria of the World Health Organization (WHO) are based on bidimensional measurement of lesion size [8] and the Response Evaluation Criteria in Solid Tumors (RECIST) [9] are based on unidimensional lesion measurement. However, after transarterial embolization, tumour necrosis (manifest as a lack of tumour enhancement) may be seen before any changes in tumour size become apparent, and in some cases, necrosis may not be accompanied by any reduction in tumour size. Consequently, the European Association for the Study of the Liver (EASL) proposed a system for assessing treatment response in HCC based on lesion enhancement instead of lesion size [7] , and subsequently, the American Association for the Study of Liver Diseases (AASLD) proposed to incorporate changes in tumour enhancement in a modified version of RECIST (mRECIST) [10] . In recent studies, response evaluation criteria incorporating enhancement characteristics (mRECIST, EASL) predicted long-term survival of HCC patients treated with transarterial methods earlier and more accurately than did size-based criteria (e.g. WHO, RECIST) [11] [12] [13] . As a result, the use of EASL criteria to establish patients' response to transarterial embolization has increased [14] .
The EASL has never specified precisely how to apply its criteria to quantify the change in tumour enhancement [7] . In some studies investigators have estimated the percentage change in tumour enhancement visually, as is often done in clinical practice [14, 15] ; however, in other studies, the enhancing tissue has been measured unidimensionally [16] or bidimensionally [11, 17] or by using a volumetric approach [18] [19] [20] [21] . Furthermore, in all of these studies, the magnitude of response was decided in consensus without analysing interreader agreement. In clinical practice, images are hardly ever evaluated in consensus, but rather are assessed by individual radiologists of different experience levels [22] .
It is important to assess reader agreement with regard to quantitative assessments, particularly when such assessments influence patient management [22] . Thus, the purpose of our study was to evaluate interreader and inter-test agreement in applying size-and necrosis-based response assessment criteria after transarterial embolization for HCC, using two different methods of applying the EASL criteria.
Materials and methods

Patients
From November 2007 through March 2012, 92 patients undergoing transarterial embolization using microspheres for surgically unresectable HCC were included in a prospective trial (ClinicalTrials.gov Identifier: NCT00539643) aimed at comparing the effect between embolization using Bead Block™ microspheres versus doxorubicin-loaded LC Bead™. Diagnosis of HCC was based on the EASL criteria [7] . For our retrospective analysis, patients were excluded if their imaging follow-up was not performed by CT or if there was no target lesion, defined as a nodular, non-infiltrative lesion with a diameter of at least 1 cm permitting repetitive measurement according to the mRECIST guidelines [10, 11] . Further inclusion and exclusion criteria are shown in Supplemental Table 1. CT acquisition and follow-up Triphasic CTs were acquired on a multidetector CT (LightSpeed 16, VCT and CT750, GE Medical Systems, Milwaukee, Wis) using the following parameters: slice thickness, 5 mm for all phases; pitch, 0.984-1.375; gantry rotation time, 0.7-0.8 s; ref. tube current-time, 220-440 mA/rotation; tube voltage, 120 kV. After unenhanced images were acquired, additional images were acquired in the hepatic arterial phase (using bolus tracking) and portal venous phase (40 s after the hepatic arterial phase). For enhanced phases, 150 mL of iohexol 300 (Omnipaque, GE Healthcare, Waukesha, Wis) was administered intravenously with a power injector at 4 mL/s.
Baseline CT was performed 22.6±14.4 days (range, 3-63 days) before the start of transarterial embolization. A first follow-up CT (1st FU) was planned for 2-3 weeks after transarterial embolization and a second follow-up CT (2nd FU) was planned for 10-12 weeks after transarterial embolization.
Embolization procedure
Patients were randomized to undergo embolization of the lesion with Bead Block™ microspheres or with doxorubicinloaded LC Bead™. The embolization technique used has been described before [4, 23] . After visceral angiography was performed to establish hepatic arterial anatomy, tumour burden and vascular supply, vessels supplying the target lesion(s) were catheterized and embolization was performed with either LC Bead™ loaded with 150 mg of doxorubicin, or Bead Block™, beginning in either case with 100-to 300-micron particles until stasis was achieved. In the LC Bead™ group, if stasis was not achieved after the entire dose of doxorubicinloaded microspheres had been delivered, additional Bead Block™ was used to achieve the stasis endpoint. If multiple small lesions were present, lobar embolization was performed instead of selective embolization. After the embolization, all patients were admitted for intravenous hydration, 24 h of antibiotic treatment, pain control and observation.
Image analysis and assessment of response Four radiologists (RKGD and SSK, faculty members and OFD and AMH, body imaging research fellows, with 8, 10, 5 and 4 years of experience in interpreting abdominal CT, respectively) independently evaluated the CT data using electronic forms for data collection. The radiologists were blinded to clinical and laboratory findings as well as histological and imaging findings. In patients with unifocal HCC, the radiologists assessed the targeted tumour, and in patients with multifocal HCC, they selected the two largest and most easily measured lesions [24] . A target lesion was defined as a nodular, non-infiltrative lesion with a diameter of at least 1 cm permitting repetitive measurement according to mRECIST guidelines [10, 11] . Response was assessed using criteria based on size (WHO, RECIST) and necrosis (mRECIST, EASL) [7] [8] [9] [10] .
The readers measured the largest diameter(s) of the relevant lesion(s) uni-and bidimensionally in accordance with RECI ST and WHO guidelines, respectively. To implement EASL criteria, visual volumetric assessment of enhancing tissue was performed by scrolling through all CT images covering the respective lesion and estimating the total percentage of enhancing tissue within the relevant lesion(s) in 10-percentile increments (an estimate henceforth referred to as EASL est ); in addition, on the transaxial slice with the largest enhancing component, they measured the enhancing tissue bidimensionally (a measurement henceforth referred to as EASL meas ). The longer of the two dimensions recorded as EASL meas was later used to apply mRECIST. Visual assessment of enhancing tissue was performed before measurement to avoid influencing the estimation of enhancing tissue. As microspheres were used for transarterial embolization, there were no Lipiodol-induced artefacts hampering visual assessment. As per the various response assessment criteria (Table 1) , responses were classified into four categories: complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD).
Statistical analysis
The Wilcoxon rank-sum test for continuous variables and Fisher's exact test for categorical variables were used to examine demographic characteristic differences between patients who underwent embolization with Bead Block™ microspheres or with doxorubicin-loaded LC Bead™.
Weighted kappa statistics with quadratic weights were used to assess agreement with regard to the four response categories (CR, PR, SD and PD) between two different response criteria at each follow-up scan for each reader [25] . Light's kappa based on weighted kappa with quadratic weights was calculated to assess agreement between the four readers. The 95 % confidence interval (CI) of the kappa was estimated using bootstrapping with 2,000 repetitions. To further assess EASL est and EASL meas , because of the observed bimodal distribution, we first reported the percentage CR by all four readers by both EASL assessments for each reader; for the remaining patients, we evaluated agreement on percentage change by calculating the intraclass correlation coefficient (ICC). A logarithm transformation was applied when calculating the ICC because of the skewness of the data. Kappa (κ) and ICC values were interpreted as follows: 0.00-0.20, slight agreement; 0.21-0.40, fair agreement; 0.41-0.60, moderate agreement; 0.61-0.80, substantial agreement; and 0.81-1.00, excellent agreement [26] .
Statistical analyses were performed using the software packages SAS 9.2 (SAS Institute Inc., Cary, NC, USA) and R version 2.13 (The R Foundation for Statistical Computing).
Results
Of the 92 patients who fulfilled the inclusion criteria, 17 were excluded from our retrospective analysis because the target lesion on the baseline CTs did not meet mRECIST criteria [10, 11] , and one was excluded because follow-up imaging was performed by MRI instead of CT (Fig. 1) . The Fig. 1 Flowchart of patient selection. TAE transarterial embolization, HCC hepatocellular carcinoma demographic characteristics of the 74 patients included in the study are summarized in Table 2 . The mean time interval between transarterial embolization and 1st FU was 18.1±4.9 days (range, 9-46 days). Seventy of the 74 patients (95 %) underwent a 2nd FU at a mean of 87.8±20.1 days (range, 62-183 days) after transarterial embolization. Of the four patients who did not have a 2nd FU, one was taken off protocol upon request, one demonstrated disease progression, one died before the 2nd FU and one had not yet had the 2nd FU at the time of data analysis.
Interreader agreement for WHO, RECIST, mRECIST and EASL criteria Table 3 shows that for all criteria except the WHO criteria, interreader agreement in categorizing response was substantial, with κ values ranging from 0.631 to 0.780. For WHO criteria, interreader agreement was moderate at 1st FU (κ=0.578) and substantial at 2nd FU (κ=0.716). There were no significant differences in the interreader agreement levels of the various criteria, and confidence intervals of κ values overlapped for all criteria assessed (Table 3) . Agreement between the four readers regarding treatment response category (CR, PR, SD, PD) was substantial for EASL meas (κ=0.700 and κ=0.765 for 1st and 2nd FU, respectively) and EASL est (κ=0.698 and κ=0.746 for 1st and 2nd FU, respectively) ( Table 3 , Fig. 2 ).
Inter-test agreement between EASL meas and EASL est
Inter-test agreement regarding treatment response category (CR, PR, SD, PD) between EASL meas and EASL est was excellent for all four readers at both FU time points (Table 3) . Inter-test agreement was higher between EASL meas and EASL est than between WHO and RECIST (Table 3, Fig. 3 ). (Table 4) .
Discussion
We evaluated interreader agreement in applying size-and necrosis-based response assessment criteria in patients who underwent transarterial embolization for HCC. In addition, we evaluated interreader and inter-test agreement between two different methods of applying the EASL criteria-one in which the change in enhancement was estimated visually (as EASL est ), and one in which the change was measured bidimensionally (as EASL meas ). Agreement between the four readers in categorizing response was substantial for both methods of applying the EASL criteria. Furthermore, intertest agreement between EASL est and EASL meas was excellent at two follow-up points. Radiologic evaluation plays a central role in assessing the response to transarterial embolization in patients with HCC. Various response assessment criteria have been proposed [7] [8] [9] [10] and different criteria are being applied in different institutions. The variety of different criteria has led to efforts by organizations such as the American College of Radiology (ACR) Liver Imaging Reporting and Data System (LI-RADS) to create a standardized method to assess tumour response after transarterial embolization of HCC (Claude Sirlin, chair of ACR LI-RADS committee, personal communication). In recent studies, classifications of response based on radiologic criteria have been found to correlate significantly with outcomes [11, 27] or histopathologic findings [12, [28] [29] [30] [31] . In patients with HCC, transarterial embolization techniques have been shown to cause necrosis even when tumour size has not yet decreased; therefore, after embolization, necrosis-based criteria may predict outcomes earlier than size-based criteria [11, 12, 28, 30] . However, in all these studies-in contrast to clinical practice-the classifications were based on the consensus of two or more readers [22] . One recent study investigating interreader variability of RECIST and WHO criteria in a heterogeneous patient group undergoing various antineoplastic treatments demonstrated moderate to substantial agreement, with κ values of 0.54 and 0.61, respectively [32] . These results are in accordance with our findings regarding these sizebased criteria, even though the patient population and treatment methods assessed in our study were quite different. Necrosis-based criteria may reflect tissue changes after transarterial embolization earlier than size-based criteria and therefore allow for earlier assessment of treatment response. While it may be assumed that regions of enhancement are more difficult to define and measure than lesion size and therefore may be less reproducible, our data shows that interreader agreement for necrosisbased criteria was not inferior to that of size basedcriteria.
Unlike RECIST, mRECIST and WHO guidelines, the EASL guidelines do not precisely state the method by which tumour response should be calculated [7] . As a result, investigators have interpreted the EASL guidelines in various ways, using visual estimation [14, 15] , unidimensional [16] , bidimensional [11, 17] or volumetric measurements [18] [19] [20] [21] to estimate enhancing tissue. In our study, the readers estimated the percentage of enhancing tissue visually and also measured the largest area of tumour enhancement uni-and bidimensionally on one slice; volumetric evaluation was not performed, because of the time constraints due to limited technical and personnel resources frequenty encounteredin clinical practice. The fact that agreement between the two methods EASL meas and EASL est was excellent for all readers suggests that visual assessment of enhancing tissue is an adequate method to use in clinical practice. Moreover, because it is less time-consuming and less disruptive of the interpretation process, it may be the preferable approach for interpreting the EASL guidelines in clinical practice.
Our study had a number of limitations. First, we were not able to use histopathologic correlation to validate the treatment responses determined with the different response criteria, as our patients did not undergo subsequent resection, transplantation or autopsy after transarterial embolization. Second, our study included patients treated with two different methods of transarterial embolization, and subanalyses of the two groups were not performed because of the limited sample size. However, for assessment of interreader agreement, we assumed that the two different methods of transarterial embolization would not significantly influence our measurements. Third, patients with infiltrating lesions were excluded from analysis, as these lesions are not regarded as measurable according to response assessment guidelines [9, 10] . Fourth, in case of discrepancies in assessment of treatment response between readers, a conclusive decision on the actual treatment response could not reliably be assessed because of the lack of a standard of reference. Finally, we used CT to evaluate treatment response. While MRI may have benefits when Lipiodol limits the usefulness of CT [33] , in our patient cohort Lipiodol was not used and in many institutions CT is the main modality for postoperative follow-up after transarterial embolization and may even be used during the intervention [34] .
In summary, this study demonstrates that after transarterial embolization for HCC, there is substantial interreader agreement in applying both size-and necrosis-based response assessment criteria. In addition, it shows that inter-test agreement between visual estimation and bidimensional measurement of enhancing tissue is excellent, which suggests that these two methods can be used interchangeably to evaluate treatment response of HCC after transarterial embolization. In the 2nd follow-up CT (b, e), 84 days after locoregional treatment, the area marked with arrowheads was judged by one reader as normal enhancing liver parenchyma, resulting in a response evaluation of CR (complete response). Another reader judged the same area (arrowheads in b and e) as remaining tumour tissue, resulting in a response evaluation of PR (partial response). The discrepancy in response evaluation was present for EASL meas as well as EASL est . A further available control scan 176 days after transarterial embolization (c, f) more clearly depicts the area as remaining enhancing tumour tissue (arrowheads in c and f) Fig. 3 Axial slices of noncontrast CT (a, d) and arterial phase CT (b, e) of a 66-year-old man with HCC in liver segment I. In the 2nd follow-up CT (b, e), 76 days after locoregional treatment, the bidimensional measurement of the remaining enhancing tumour tissue (EASL meas ; arrows in e) indicated a decrease of 20 % as compared to the baseline scan and therefore resulted in a response evaluation of SD (stable disease). By visual estimation (EASL est ), the same reader judged the reduction in enhancing tumour tissue to be 70 %, resulting in a response evaluation of PR (partial response). This visual estimation of reduced enhancing tumour tissue (arrowhead in f) is supported by the coronal reconstructions of the tumour shown on the baseline CT (c) and at 2nd follow-up (f) 
